🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

LEAP India, Molbio Diagnostics secure SEBI nod for IPO

EntrackrEntrackr · 11d ago
LEAP India, Molbio Diagnostics secure SEBI nod for IPO
Medial

LEAP India, Molbio Diagnostics secure SEBI nod for IPO Logistics solutions firm LEAP India and Goa-based molecular diagnostics company Molbio Diagnostics have secured approval from the Securities and Exchange Board of India (SEBI) to launch their initial public offering (IPO). The regulator’s observations, published recently, mark a significant milestone for both companies as they prepare to enter the public markets. The approvals come months after LEAP India filed its draft red herring prospectus (DRHP) to raise up to Rs 2,400 crore. The issue comprises a fresh issue of Rs 400 crore and an offer for sale (OFS) of Rs 2,000 crore. The OFS will be led primarily by Vertical Holdings II Pte. Ltd., a promoter entity backed by global investment firm KKR, which plans to divest shares worth Rs 1,998.6 crore. Another promoter group entity, KIA EBT Scheme 3, will offload shares worth around Rs 13.8 crore. Ahead of its plans to go public, the company converted itself into a public limited entity in July 2025 and appointed independent directors to strengthen its board, a development earlier reported exclusively by Entrackr. LEAP India, which provides pallet, container, and asset-pooling solutions to large FMCG, e-commerce, and pharma companies, has been expanding its fulfilment centres and customer touchpoints to tap the surge in demand for organised supply-chain infrastructure. In FY25, the firm reported 28% YoY revenue growth to Rs 466 crore, while maintaining its Rs 37.5 crore PAT, on the back of higher asset utilisation. Meanwhile, in August 2025, Molbio Diagnostics filed its DRHP proposing a fresh issue of Rs 200 crore and an OFS of up to 1.25 crore shares. Selling shareholders include Exxora Trading LLP, Dr Chandrasekhar Bhaskaran Nair, Abdul Qadir Mohamed Theruvath, among others. Molbio, known for its Truenat point-of-care molecular testing platform deployed across TB, HPV, COVID-19, and other infectious diseases, plans to use the IPO proceeds to expand manufacturing capacity and boost R&D infrastructure. The company logged Rs 1,020 crore in revenue and Rs 138.5 crore profit in FY25, reaffirming the growing demand for decentralised diagnostics solutions in India and emerging markets.

Related News

Molbio Diagnostics posts Rs 1,020 Cr revenue, Rs 138 Cr PAT in FY25

EntrackrEntrackr · 3m ago
Molbio Diagnostics posts Rs 1,020 Cr revenue, Rs 138 Cr PAT in FY25
Medial

Goa-based molecular diagnostics firm Molbio closed FY25 with Rs 1,020 crore in revenue and Rs 138.5 crore profit, marking a sharp recovery from its post-COVID slump. The Temasek-backed unicorn, which had shot into the limelight during the pandemic, saw its revenue peak at Rs 1,272 crore in FY21 before crashing to Rs 332 crore in FY23. According to its draft red herring prospectus (DRHP) filed with SEBI, Molbio’s scale grew 22% from Rs 836 crore in FY24 while its profits surged 66% during FY25, underlining the company’s turnaround ahead of its proposed public listing. The growth was largely powered by its flagship Truenat platform, a portable, battery-operated molecular testing system used for tuberculosis and over 30 other infectious diseases. As per the DRHP, the company claims to have sold 2,180 devices with 12.24 million test kits in FY25. Molbio’s total expenses grew 25% to Rs 820 crore in FY25. Raw material consumption accounted for more than half of the cost base at Rs 413 crore, while employee benefits rose 61% to Rs 103 crore. Advertising and marketing spend nearly doubled to Rs 22 crore. At the same time, the company’s EBITDA margin stood at 26.17% while return on capital employed (ROCE) was at 22.06% in FY25. On a unit level, it spent Rs 0.80 to earn a rupee of revenue, compared to Rs 0.82 in FY24. The company currently operates five manufacturing units across Goa, Bengaluru, and Visakhapatnam, with an installed capacity of 3,600 Truenat devices and 3.9 crore test kits annually. Backed by Temasek and Motilal Oswal Private Equity, Molbio has raised about Rs 970 crore to date. Through its IPO, Molbio plans to raise Rs 200 crore via a fresh issue, while existing shareholders will offload 1.25 crore shares through an offer for sale. The proceeds will be used for a new R&D facility, expansion of manufacturing units, and general corporate purposes. As per the DRHP, Exxora Trading LLP is the largest shareholder in Molbio with a 41.23% stake, followed by India Business Excellence Fund at 12.66%. Temasek owns 8.93%, while Gopalkrishna Mangalore Kini and Dr. Chandrasekhar Bhaskaran Nair hold 6.73% and 5.42%, respectively. Molbio has bounced back from its pandemic boom and later slump to steady growth and profits, making it one of the few healthcare startups ready to go public. Its IPO will be watched closely to gauge investor interest in diagnostics companies after COVID-19.

Download the medial app to read full posts, comements and news.